

K203390 Artimes pro Balloon Dilatation CatheterApr 14, 2021
147 days to decisionK203390 · Product code: **LOX** · Cardiovascular
Source: <https://www.510kdatabase.net/k203390/>**SUBMISSION DETAILS**

| | |
|-----------------------|--|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Traditional |
| Device classification | Catheters, Transluminal Coronary Angioplasty, Percutaneous (LOX) |
| Date received | Nov 18, 2020 |
| Decision date | Apr 14, 2021 |
| Days to decision | 147 days |
| Third-party review | No |
| Combination product | No |
| PCCP authorized | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---------------------------------------|
| Company | Brosmed Medical Co., Ltd. |
| Location | Dongguan, CN |
| Contact | Wade Zhang |
| 510(k) history | 8 submissions · 8 cleared · 2016-2025 |

REGULATORY CONSULTANT

| | |
|-----------------|---|
| Consulting firm | Eminence Clinical Research, Inc. |
| Contact | Diane Horwitz |

Regulatory consulting firm that managed this 510(k) submission on behalf of the applicant. Source: [FDA accessdata.fda.gov](https://accessdata.fda.gov)**CLINICAL EVIDENCE - NCT03301246****Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease**

| | |
|-------------------|---|
| Status | Completed - <i>No results published to ClinicalTrials.gov</i> |
| Enrollment | 60 patients (actual) |
| Study sites | 2 sites |
| Condition studied | Coronary Artery Disease; Heart Disease, Ischemic; Coronary Stenosis |
| Primary purpose | Treatment |
| Study type | Interventional |
| Study design | Single group |
| Masking | Open label |
| Completion date | May 8, 2020 |
| Sponsor | Eminence Clinical Research, Inc. (Industry) |

Primary outcome**Procedure Success****Secondary outcome****Anticipated Adverse Events**Source: [ClinicalTrials.gov](https://clinicaltrials.gov) / U.S. National Library of Medicine - clinicaltrials.gov/study/NCT03301246